Clinical utility and future perspectives of liquid biopsy in colorectal cancer
Liquid biopsy analyses of circulating tumor DNA are emerging as transformative tools for colorectal cancer management, enabling disease detection, monitoring, and treatment. Here, we critically assess its evidence-based utility in current clinical practice, seeking to align physicians’ and patients’ expectations. Patelli et al. critically evaluate the clinical utility of liquid biopsy-based circulating tumor DNA (ctDNA) analyses in colorectal cancer management. By addressing its applications across metastatic, locoregional, and early disease settings, the authors highlight both the transformative potential and current limitations of ctDNA in guiding personalized treatment decisions.
Authors
- Giorgio Patelli (ORCID: https://orcid.org/0000-0001-8697-2158)
- Giovanni Crisafulli (ORCID: https://orcid.org/0000-0002-5511-1555)
- Andrea Sartore‐Bianchi (ORCID: https://orcid.org/0000-0003-0780-0409)
- Salvatore Siena (ORCID: https://orcid.org/0000-0002-2681-2846)
- Alberto Bardelli (ORCID: https://orcid.org/0000-0003-1647-5070)
- Silvia Marsoni (ORCID: https://orcid.org/0000-0002-5361-7122)
- Luca Lazzari (ORCID: https://orcid.org/0000-0001-6841-4240)
Institutions
- University of Milan (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- IFOM (IT)
- University of Turin (IT)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1038/s43856-025-00852-4
- Citations
- 8
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 7.49
Funders
- Cancer Research UK
- European Commission
- Associazione Italiana per la Ricerca sul Cancro